ADVENTRX Announces Appointment of Veteran Finance and Biotech Industry Executive Gregory P. Hanson as Chief Financial Officer
December 20 2006 - 6:00AM
PR Newswire (US)
SAN DIEGO, Dec. 20 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing low development risk
pharmaceuticals, announced today the appointment of veteran
financial executive, Gregory P. Hanson, MBA, CMA, as Chief
Financial Officer, Senior Vice President and Treasurer. In
connection with Mr. Hanson's appointment, Robert A. Daniel,
previously the Company's Acting Chief Financial Officer and
Treasurer, will resume his prior role as the Company's Controller.
"We are pleased to have recruited Greg to our team," said Evan
Levine, ADVENTRX chief executive officer. "His achievements as well
as expertise in the financial management of public and private
biotech and high tech companies will make a significant
contribution to the financial and strategic development of our
company. In addition, I would like to thank Bob for taking on the
role of Acting Chief Financial Officer." Mr. Hanson joins the
Company from Avanir Pharmaceuticals, a publicly traded drug
discovery and development company, where he served as Vice
President and Chief Accounting Officer from May 2006 to December
2006, and as Vice President and Chief Financial Officer from July
1998 to May 2006. During Mr. Hanson's tenure at Avanir, he
simultaneously served in other executive capacities, including
Corporate Compliance Officer since 2002 and Corporate Secretary
since July 1998. From September 1995 to July 1998, Mr. Hanson
served as Chief Financial Officer of XXsys Technologies, Inc., a
publicly- traded company focused on the commercialization of
advanced composite technologies; and from May 1993 to September
1995, he held a number of financial positions with The Titan
Corporation, a diversified telecommunications and information
systems company, including acting Chief Financial Officer and
acting Controller for its subsidiary, Titan Information Systems.
Earlier in his career, Mr. Hanson held various management positions
with Ford Motor Company over a 14-year span and Solar Turbines
Incorporated, a subsidiary of Caterpillar Inc., over a 3-year span.
Mr. Hanson received a B.S. in Mechanical Engineering from Kansas
State University and an M.B.A. with honors from the University of
Michigan. He is a Certified Management Accountant and has passed
the examination for Certified Public Accountants. Mr. Hanson has
been a member of the Financial Accounting Standards Board's Small
Business Advisory Committee since April 2004 and serves on its
Agenda Committee. As the Company's Chief Financial Officer, Mr.
Hanson will be responsible for managing the Company's financial
affairs, including its accounting, tax and financial reporting
obligations. About ADVENTRX Pharmaceuticals ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on commercializing low development risk
pharmaceuticals for cancer and infectious disease that enhance the
efficacy and/or safety of existing therapies. More information can
be found on ADVENTRX's web site at http://www.adventrx.com/.
Forward Looking Statement ADVENTRX cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements that involve risks,
uncertainties, assumptions and other factors that, if they do not
materialize or prove to be accurate, could cause ADVENTRX's results
to differ materially from historical results or those expressed or
implied by such forward-looking statements. Such forward-looking
statements are made based on management's current expectations and
beliefs and should not be regarded as a statement or representation
by ADVENTRX that any of its plans, including its anticipated
milestones, will be achieved on time or at all. The potential risks
and uncertainties that could cause actual results to differ
materially include, but are not limited to: successfully educating
new executives and integrating new executives with existing
executives and management; and other risks and uncertainties more
fully described in ADVENTRX's press releases and periodic filings
with the Securities and Exchange Commission. ADVENTRX's public
filings with the Securities and Exchange Commission are available
at http://www.sec.gov/. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date when made. All forward-looking statements are qualified
in their entirety by this cautionary statement and ADVENTRX assumes
no obligation to revise or update any forward-looking statement,
including as set forth in this press release, to reflect events or
circumstances arising after the date on which it was made.
DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Ioana C. Hone
of ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024